Todd C. Brady, President and CEO of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), acquired a significant block of the company’s common stock, according to a recent SEC filing.
On June 3, 2026, Mr. Brady purchased 250,000 shares of Aldeyra Therapeutics common stock. The transactions totaled $418,450, with prices ranging from $1.64 to $1.70 per share.
Following these acquisitions, Mr. Brady directly holds 1,721,298 shares of Aldeyra Therapeutics common stock. The insider purchase comes as the stock has declined 62.55% over the past six months, currently trading at $1.63 with a market cap of $97.72 million. According to InvestingPro analysis, the stock appears undervalued relative to its Fair Value, placing it among opportunities on the most undervalued stocks list. InvestingPro offers 10 additional exclusive tips for ALDX subscribers.
In other recent news, Aldeyra Therapeutics received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) rejecting its New Drug Application for reproxalap, a treatment for dry eye disease. The FDA cited inconsistencies in study results and a lack of substantial evidence from well-controlled investigations to support the drug’s effectiveness. Following this setback, H.C. Wainwright downgraded Aldeyra’s stock rating to Neutral from Buy and lowered its price target to $2.00 from $10.00. Conversely, BTIG maintained a Buy rating on the stock, with a price target of $9.00, despite the FDA’s concerns. In financial developments, Aldeyra repaid a $15 million loan to Hercules Capital, leading to the termination of its credit facility. Additionally, Martin J. Joyce, a member of Aldeyra’s Board of Directors, announced he will not stand for re-election at the upcoming 2026 annual meeting. These events mark significant developments for Aldeyra Therapeutics as the company navigates regulatory and financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.